

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> U.S. Patent 7,973,137	)	
SCHNECK <i>et al.</i>	)	Confirmation No. 9271
Serial No.: 09/642,660	)	Group Art Unit: 1642
Filed: August 22, 2000	)	Examiner: S. Aeder
	)	Atty Dkt No: 001107.00042

For: **CELL COMPOSITIONS COMPRISING MOLECULAR  
COMPLEXES THAT MODIFY IMMUNE RESPONSES**

**REQUEST FOR CERTIFICATE OF CORRECTION**

U.S. Patent and Trademark Office  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

Please issue a Certificate of Correction to correct the priority information on the face of U.S. Patent 7,973,137. "09/074,276" should be "09/063,276." We believe this is not our error; copies of the inventors' declaration and the official filing receipt, both correctly indicating "09/063,276," are attached. However, if a fee is due, please charge our Deposit Account No. 19-0733 if a fee is due.

Respectfully submitted,

**BANNER & WITCOFF, LTD.**

/Lisa M. Hemmendinger/

By: \_\_\_\_\_  
Lisa M. Hemmendinger  
Registration No. 42,653

Dated: July 15, 2011

Banner & Witcoff, Ltd.  
1100 13<sup>th</sup> Street, N.W., Suite 1200  
Washington, D.C. 20005-4051

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO.: 7,973,137  
DATED: July 5, 2011  
INVENTOR(S): Schneck et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Related U.S. Application Data:

Delete "09/074,276" and insert --09/063,276--

# JOINT DECLARATION FOR PATENT APPLICATION

As the below named inventor, we hereby declare that:

Our residence, post office address and citizenship are as stated below next to our names;

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled MOLECULAR COMPLEXES WHICH MODIFY IMMUNE RESPONSES

the specification of which

☐ is attached hereto.

☒ was filed on April 21, 1998 as Application Serial Number 09/063,276 and was amended on \_\_\_\_\_ (if applicable).

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

## Prior Foreign Application(s)

We hereby claim foreign priority benefit under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority	Application Number	Filing Date	Country	Applicant

## Prior United States Application(s)

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

United States Application Number	Filing Date	Status
08/828,712	03/28/97	Pending
60/014,367	03/25/96	Abandoned

And we hereby appoint, both jointly and severally, as our attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith the following attorneys who are all members of the Bar of the District of Columbia, their registration numbers being listed after their names:

Donald W. Besser, Registration No. 17,037; William W. Beckett, Registration No. 18,262; Dale H. Hoeschelt, Registration No. 19,090; Joseph M. Poterzo, Registration No. 28,173; Alan I. Carter, Registration No. 28,163; James A. Niegowski, Registration No. 28,331; Barry L. Grossman, Registration No. 30,844; Joseph M. Sharpton, Registration No. 29,864; Thomas L. Peterson, Registration No. 30,969; Nina L. Doolock, Registration No. 29,673; William J. Fisher, Registration No. 32,133; Thomas E. Jackson, Registration No. 29,808; and Seth A. Kagan, Registration No. 32,141.

All correspondence and telephone communications should be addressed to Banner & Witcoff, Ltd., Eleventh Floor, 1001 G Street, N.W., Washington, D.C. 20001-4597, telephone number (202) 508-9100, which is also the address and telephone number of each of the above listed attorneys.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature [Signature] Date 09/02/96  
 Full Name of First Inventor SCHEINECK Jonathan First Given Name Second Given Name  
 Family Name

Residence 5 Yeatman Court, Silver Spring, Maryland 20902

Citizenship United States of America

Post Office Address Same as Above

Signature [Signature] Date 09/02/98  
 Full Name of Second Inventor O'HERRIN Scott First Given Name Second Given Name  
 Family Name

Residence 110 West 39th Street Apt. 1400, Baltimore, Maryland 21210

Citizenship United States of America

Post Office

Address Same as Above

Signature [Signature] Date 09/02/98  
 Full Name of Third Inventor LEHOWITZ Michael First Given Name Second Given Name  
 Family Name

Residence 7504 Slade Avenue, Pikesville, Maryland 21208

Citizenship United States of America

Post Office

Address Same as Above

Signature [Signature] Date 02/09/98  
 Full Name of Fourth Inventor HAMAD Abdul First Given Name Second Given Name  
 Family Name

Residence 3121 Normandy Woods Drive, Apt. H, Ellicott City, Maryland 21043

Citizenship Budan

Post Office

Address Same as Above

LAW OFFICES  
 BANNER & WITCOFF, LTD.  
 1001 G STREET, N.W.  
 WASHINGTON, D.C. 20001-4597  
 (202) 508-9100

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	001107.00042
		Application Number	
Title of Invention	CELL COMPOSITIONS COMPRISING MOLECULAR COMPLEXES THAT MODIFY IMMUNE RESPONSES		
<p>The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.</p> <p>This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.</p>			

**Secrecy Order 37 CFR 5.2**

- ☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

**Applicant Information:**

<b>Applicant 1</b>				
<b>Applicant Authority</b> <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>	<b>Suffix</b>
	Jonathan		Schneck	
<b>Residence Information (Select One)</b> <input checked="" type="radio"/> US Residency <input type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
<b>City</b>	Silver Spring	<b>State/Province</b>	MD	<b>Country of Residence</b> <sup>2</sup>
				US
<b>Citizenship under 37 CFR 1.41(b)</b> <sup>1</sup>				
US				
<b>Mailing Address of Applicant:</b>				
<b>Address 1</b>		c/o The Johns Hopkins University		
<b>Address 2</b>		720 Rutland Avenue		
<b>City</b>	Baltimore	<b>State/Province</b>	MD	
<b>Postal Code</b>		21205	<b>Country</b>	US
<b>Applicant 2</b>				
<b>Applicant Authority</b> <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>	<b>Suffix</b>
	Sean		O'Herrin	
<b>Residence Information (Select One)</b> <input checked="" type="radio"/> US Residency <input type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
<b>City</b>	Baltimore	<b>State/Province</b>	MD	<b>Country of Residence</b> <sup>2</sup>
				US
<b>Citizenship under 37 CFR 1.41(b)</b> <sup>1</sup>				
US				
<b>Mailing Address of Applicant:</b>				
<b>Address 1</b>		c/o The Johns Hopkins University		
<b>Address 2</b>		720 Rutland Avenue		
<b>City</b>	Baltimore	<b>State/Province</b>	MD	
<b>Postal Code</b>		21205	<b>Country</b>	US
<b>Applicant 3</b>				
<b>Applicant Authority</b> <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>	<b>Suffix</b>
	Michael	S.	Lebowitz	
<b>Residence Information (Select One)</b> <input checked="" type="radio"/> US Residency <input type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
<b>City</b>	Pikesville	<b>State/Province</b>	MD	<b>Country of Residence</b> <sup>2</sup>
				US

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	001107.00042
		Application Number	
Title of Invention	CELL COMPOSITIONS COMPRISING MOLECULAR COMPLEXES THAT MODIFY IMMUNE RESPONSES		

<b>Citizenship under 37 CFR 1.41(b)</b>		US	
<b>Mailing Address of Applicant:</b>			
<b>Address 1</b>		c/o The Johns Hopkins University	
<b>Address 2</b>		720 Rutland Avenue	
<b>City</b>	Baltimore	<b>State/Province</b>	MD
<b>Postal Code</b>	21205	<b>Country</b>	US
<b>Applicant 4</b>			
<b>Applicant Authority</b>		<input checked="" type="radio"/> Inventor <input type="radio"/> Legal Representative under 35 U.S.C. 117 <input type="radio"/> Party of Interest under 35 U.S.C. 118	
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>
	Abdel		Hamad
<b>Residence Information (Select One)</b> <input checked="" type="radio"/> US Residency <input type="radio"/> Non US Residency <input type="radio"/> Active US Military Service			
<b>City</b>	Ellicott City	<b>State/Province</b>	MD
<b>Country of Residence</b>		US	
<b>Citizenship under 37 CFR 1.41(b)</b>		SD	
<b>Mailing Address of Applicant:</b>			
<b>Address 1</b>		c/o The Johns Hopkins University	
<b>Address 2</b>		720 Rutland Avenue	
<b>City</b>	Baltimore	<b>State/Province</b>	MD
<b>Postal Code</b>	21205	<b>Country</b>	US
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the <b>Add</b> button. <span style="float: right;"><b>Add</b></span>			

### Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).	
<input type="checkbox"/> An Address is being provided for the correspondence information of this application.	
<b>Customer Number</b>	22907
<b>Email Address</b>	<input type="button" value="Add Email"/> <input type="button" value="Remove Email"/>

### Application Information:

<b>Title of the Invention</b>	CELL COMPOSITIONS COMPRISING MOLECULAR COMPLEXES THAT MODIFY IMMUNE RESPONSES		
<b>Attorney Docket Number</b>	001107.00042	<b>Small Entity Status Claimed</b>	<input checked="" type="checkbox"/>
<b>Application Type</b>	Nonprovisional		
<b>Subject Matter</b>	Utility		
<b>Suggested Class (if any)</b>		<b>Sub Class (if any)</b>	
<b>Suggested Technology Center (if any)</b>			
<b>Total Number of Drawing Sheets (if any)</b>	21	<b>Suggested Figure for Publication (if any)</b>	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	001107.00042
		Application Number	
Title of Invention	CELL COMPOSITIONS COMPRISING MOLECULAR COMPLEXES THAT MODIFY IMMUNE RESPONSES		

**Publication Information:**
☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

**Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

**Representative Information:**

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.

Please Select One: ☒ Customer Number ☐ US Patent Practitioner ☐ Limited Recognition (37 CFR 11.9)

Customer Number 22907

**Domestic Benefit/National Stage Information:**

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.

Prior Application Status		Patented		<a href="#">Remove</a>	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
09642660	Division of	09063276	1998-04-21	6140113	2000-10-31
Prior Application Status		Patented		<a href="#">Remove</a>	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
09063276	Continuation in part of	08828712	1997-03-28	6015884	2000-01-18
Prior Application Status		Expired		<a href="#">Remove</a>	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)		
08828712	non provisional of	60014367	1996-03-28		
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the <b>Add</b> button.					

**Foreign Priority Information:**

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	001107.00042
		Application Number	
Title of Invention	CELL COMPOSITIONS COMPRISING MOLECULAR COMPLEXES THAT MODIFY IMMUNE RESPONSES		

			<a href="#">Remove</a>
Application Number	Country <sup>1</sup>	Parent Filing Date (YYYY-MM-DD)	Priority Claimed
			<input type="radio"/> Yes <input type="radio"/> No
Additional Foreign Priority Data may be generated within this form by selecting the <b>Add</b> button.			

**Assignee Information:**

Providing this information in the application data sheet does not substitute for compliance with any requirement of part 3 of Title 37 of the CFR to have an assignment recorded in the Office.			
<b>Assignee 1</b>			
If the Assignee is an Organization check here. <input checked="" type="checkbox"/>			
Organization Name	The Johns Hopkins University		
<b>Mailing Address Information:</b>			
Address 1	720 Rutland Avenue		
Address 2			
City	Baltimore	State/Province	MD
Country <sup>1</sup>	US	Postal Code	21205
Phone Number		Fax Number	
Email Address			
Additional Assignee Data may be generated within this form by selecting the <b>Add</b> button.			

**Signature:**

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.					
Signature	/Lisa M. Hemmendinger/			Date (YYYY-MM-DD)	2011-06-09
First Name	Lisa M.	Last Name	Hemmendinger	Registration Number	42653

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.